



Carcinogenic and Anti-carcinogenic Bacteria

Guest Editor:

Prof. Dr. Tomasz M. Karpiński

Department of Medical
Microbiology, Poznań University
of Medical Sciences,
Wieniawskiego 3, 61-712 Poznań,
Poland

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editor

For many years, the most known bacterial carcinogen was *Helicobacter pylori*. With the development of science, especially molecular diagnostics, including NGS, it has been noticed that other bacteria may also be involved in cancer. A particular role is currently attributed to oral pathogens (e.g., *Streptococcus* sp., *Prevotella* sp., *Fusobacterium* sp., *Porphyromonas gingivalis*, and *Capnocytophaga gingivalis*). These pathogens can have an impact on the development of oral and esophageal cancers. Many works have also shown that mainly *Fusobacterium nucleatum* and *Porphyromonas gingivalis* play an important role in the development of colorectal and pancreatic cancer. On the other hand, already in the nineteenth century, Dr. William Coley presented anti-cancer microbes, now called the Coley's toxin. Anti-carcinogenic activity may also exert probiotic bacteria (e.g., *Lactobacillus* sp.). For this Special Issue, we invite you to send original or review papers on aspects of bacterial carcinogenesis and the anti-cancer activity of bacteria.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](#)